Human ex vivo carcinoma cells produce transforming growth factor β and thereby can inhibit lymphocyte functions in vitro

Cancer Immunology Immunotherapy

Volumn 43, Issue 6, 1997, Pages 317-323

  Vánky, Farkas ^a   Nagy, Noémi ^a   Hising, Christina ^a   Sjövall, Kerstin ^b   Larson, Barbro ^c   Klein, Eva ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c Karolinska Hospital ^*

Author keywords

Human carcinoma; Lymphocyte functions; TGFB

Indexed keywords

MONOCLONAL ANTIBODY; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA;

ADULT; ARTICLE; CARCINOMA CELL; CLINICAL ARTICLE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMODULATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE FUNCTION; OVARY CARCINOMA; PRIORITY JOURNAL;

CARCINOMA; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; MALE; MELANOMA; OVARIAN NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED;

EID: 0031058008     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050339     Document Type: Article

References (41)

1. Abuja SS, Paliogianni F, Yamada H, Balow JE, Boumpas DT (1993) Effect of transforming growth factor-β on early and late activation events in human T cells. J Immunol 150:3109-3118
2. Alleva DG, Burger CJ, Elgert KD (1994) Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-α production. J Immunol 153:1674-1686
3. Arteaga CL, Hurd SD, Winnier AR, Johnson MD, Fendly BM, Forbes JT (1993) Anti-transforming growth factor (TGF)-β antibodies inhibit breast carcinoma tumorgenicity and increase mouse spleen natural killer cell activity. J Clin Invest 92:2569-2576
4. Bodmer S, Srommer K, Frei K, Siepl C, Tribolet N de, Heid I, Fontana A (1989) Immunosuppression and transforming growth factor-β in glioblastoma. Preferential production of transforming growth factor-β2. J Immunol 143: 3222-3229
5. Brown PD, Wackefield LM (1990) Physicochemical activation of recombinant latent transforming growth factor-beta's 1, 2, and 3, Growth Factors 3:35-44
6. Bøyum A (1974) Separation of blood leukocytes, granulocytes and lymphocytes. Tissue Antigens 4:269-274
7. Cone JL, Brown DR, DeLarco JL (1988) An improved method of purification of transforming growth factor, type β, from platelets. Anal Biochem 168:71-74
8. Derynck R, Goeddel DVAU, Gutterman JU, Williams RD, Bringman DS, Berger WH (1987) Synthesis of messenger RNA for transforming growth factor alpha and beta and the epidermal growth factor receptor by human tumors. Cancer Res 47:707-712
9. Eklöv S, Funa K, Nordgren H, Olofsson A, Kanzaki T, Miyazono K, Nilsson S (1993) Lack of the latent transforming growth factor β binding protein in malignant but not in benign prostatic tissue. Cancer Res 53:3193-3197
10. Fischer JR, Darjes H, Schindel M, Drings P, Krammer PH (1994) Constitutive secretion of bioactive transforming growth factor β1 by small cell lung cancer cell lines. Eur J Cancer 30A:2125-2129
11. Garrido F, Cabrera T, Concha A, Glew S, Ruiz-Cabello F, Stern PL (1993) Natural history of HLA expression during tumour development. Immunol Today 14:491-199
12. Higgins KA, Perez JR, Coleman TA, Dorshkind K, McComas WA, Sarmiento UM, Rosen CA, Narayanan R (1993) Antisense inhibition of the p65 subunit of NF-κB blocks tumorgenicity and causes tumor regression. Proc Natl Acad Sci USA 90:9901-9905
13. Hogg N, Landis C (1993) Adhesion molecules in cell interaction. Curr Opin Immunol 5:383-390
14. Ito N, Kwata S, Tamura S, Takaishi K, Shirai Y, Kiso S, Yabuuchi I, Matsuda Y, Nishioka M, Tarai S (1991) Elevated levels of transforming growth factor β messenger RNA and its polypeptide in human hepatocellular carcinoma. Cancer Res 51:4080-4083
15. + T lymphocytes. Int Immunol 6:631-638
16. Julius MH, Simpson E, Herzenberg LA (1973) Rapid method for the isolation of functional thymus-derived murine lymphocytes. Eur J Immunol 3:645-649
17. Klein E, Kedar E, Wang P, Vánky F (1991) Recognition of transformed cells by autologous lymphocytes: a review. In Vivo: 625-630
18. Kloen P, Jennings CL, Gebhardt MC, Springfield DS, Mankin HJ (1994) Expression of transforming growth factor-beta (TGF-β) receptors, TGF-β1 and TGF-β2 production and automne growth control in osteosarcoma cells. Int J Cancer 58:440-445
19. + T cells by transforming growth factor-β1. J Immunol 151:668-677
20. Massagué J, Cheifetz S, Laiho M, Ralph DA, Wies FMB, Zentella A (1992) Transforming growth factor-β. Cancer Surv 12:81-103
21. Miescher S, Whiteside TL, Carrel S, Flounder V von (1986) Functional properties of tumor-infiltrating lymphocytes and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferate responses of lymphocytes. J Immunol 136:1899-1907
22. Miotti S, Canevari S, Ménard S, Mezzanzanica D, Porro G, Pupa S, Regazzoni M, Tagliabue E, Colnaghi M (1987) Characterization of human ovarian-associated antigens defined by novel monoclonal antibodies with tumor restrictive specificity. Int J Cancer 39:297-303
23. Miyazono K, Olofsson A, Kolosetti P, C-H, H (1991) A role of the latent TGF-β1 binding protein in the assembly and secretion of TGF-β. EMBO J 10:1091-1101
24. Nagakomi H, Petersson M, Manusson I, Juhlin C, Matsuda M, Mellstedt H, Taupin I-L, Vivier E, Andersson P, Kiessling R (1993) Decreased expression of the signal transducing ζ chains in tumor infiltrating T cells and NK cells of patients with colorectal carcinoma. Cancer Res 53:5610-5612
25. Perreault C, Brochu S, Fontaine P, Tremblay A, Pion S (1994) The role of MHC-associated self-peptides in transcription and immunosurveillance. J Immunol Immunopathol 71:130-135
26. Roberts AB, Flanders KC, Kandaiah P, Thompson NL, Obberghen-Schilling E van, Wakfield E, Rossi P, Cambrugghe B de, Heine U, Sporn MB (1988) Transforming growth factor-β: biochemistry and roles in embriogenesis, tissue repair and remodeling and carcinogenesis. Recent Prog Horm Res 44:157-168
27. Rodeck U, Bossler A, Graeven U, Fox FE, Nowell PC, Knabbe K, Kari C (1994) Transforming growth factor-β production and responsiveness in normal human melanocytes and melanoma cells. Cancer Res 54:575-581
28. Sahin U, Türeci Ö, Schmitt H, Cochlovius B, Johannes T, Schmits R, Stenner F, Luo G, Schobert I, Pfreunschuh M (1995) Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 92:11810-11813
29. Schwarz LC, Gingras M-C, Goldberg G, Greenberg AH, Wright JA (1988) Loss of growth factor dependence and conversion of transforming growth factor-β1 inhibition to stimulation in metastatic H-ras-transformed murine fibroblasts. Cancer Res 48:6999-7003
30. Shirai Y, Kawata S, Ito N, Tamara S., Takaishi K, Kisho S, Tsushima H, Matsuzawa Y (1992) Elevated levels of plasma transforming growth factor-β in patients with hepatocellular carcinoma. Jpn J Cancer Res 83:676-679
31. Sulitzeanu D (1993) Immunosuppressive factors in human cancer. Adv Cancer Res 60:247-267
32. Tada T, Ohzeki S, Utsumi K, Takiuchi H, Muramatsu M, Li X-F, Shimizu J, Fujiwara H, Hamaoka T (1991) Transforming growth factor-β-induced inhibition of T cell function. Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state. J Immuno 146:1077-1082
33. Torre-Amione G, Beauchamp RD, Koeppen H, Park BH, Schreiber H, Moses HL, Rowley DA (1990) A highly immunogenic tumor transfected with murine transforming growth factor β-1 cDNA escapes immune surveillance. Proc Natl Acad Sci USA 87:1486-1490
34. Vánky F, Willems J, Kreicbergs A, Aparisi T, Andréen M, Broström L-Å, Nilsonne U, Klein E, Klein G (1983) Correlation between lymphocyte-mediated auto-tumor reactivities and clinical course. Cancer Immunol Immonother 16:11-16
35. Vánky F, Klein E, Willems J, Böök K, Ivert T, Pétterfy A (1987) Recognition of autologous tumor cells by blood lymphocytes in patients with lung cancer. In: Byers VS, Baldwin RW (eds) Immunology of malignant disease. MTP, London, pp 105-127
36. Vánky F, Roberts T, Klein E (1987) Auto-tumor immunity in patients with solid tumors: participation of CD3 complex and MHC class I antigens in the lytic interaction. Immunol Lett 16:21-26
37. Vánky F, Stuber G, Willems J, Sjöwall K, Larsson B, Böök K, Ivert T, Péterffy A, Klein E (1988) Importance of MHC antigen expression on solid tumors in the in vitro interaction with autologous blood lymphocytes. Cancer Immunol Immunother 27:213-222
38. Vánky F, Stuber G, Rotstein S, Klein E (1989) Auto-tumor recognition following in vitro induction of MHC antigen expression on solid human tumors: stimulation of lymphocytes and generation of cytotoxicity against the original MHC antigen negative tumor cells. Cancer Immunol Immunother 28:17-21
39. Vitolo D, Kanbour A, Johnson JT, Herberman RT, Whiteside TH (1993) In situ hybridisation for cytokine gene transcripts in the solid tumour microenvironment. Eur J Cancer 29A:371-377
40. Vose BM, Vánky F, Argov S, Klein E (1977) Natural cytotoxicity in man: activity of lymph node and tumour infiltrating lymphocytes. Eur J Immunol 7:753-757
41. Vose BM, Vánky F, Fopp M, Klein E (1978) Restricted autologous lymphocyte cytotoxicity in lung neoplasia. Br J Cancer 38:375-381